Myositis-specific autoantibodies: an important tool to support diagnosis of myositis

Journal of Internal Medicine

Volumn 280, Issue 1, 2016, Pages 8-23

  Betteridge, Z ^a   McHugh, N ^a,b  

^a University of Bath   (United Kingdom)

^b ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

Author keywords

Autoantibodies; Autoimmunity; Dermatomyositis; Myositis; Polymyositis

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; AMINOACYL TRANSFER RNA; AUTOANTIBODY; AUTOANTIGEN; BIOLOGICAL MARKER; CREATINE KINASE; CYTOPLASM PROTEIN; HISTIDINE TRANSFER RNA LIGASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; JO 1 ANTIBODY; NUCLEAR MATRIX PROTEIN 2; PROTEIN ANTIBODY; SIGNAL RECOGNITION PARTICLE; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ANTIBODY DETECTION; ANTIGEN SPECIFICITY; APOPTOSIS; ASIAN; AUTOIMMUNITY; CELL INCLUSION; CLINICAL FEATURE; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; CREATINE KINASE BLOOD LEVEL; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC DIFFERENCE; ETHNIC GROUP; FOLLOW UP; FUNCTIONAL STATUS; GENETIC TRANSCRIPTION; HUMAN; IMMUNODIFFUSION; IMMUNOELECTROPHORESIS; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; INCLUSION BODY MYOSITIS; INNATE IMMUNITY; JAPANESE (PEOPLE); MUSCLE WEAKNESS; MYOSITIS; PRECIPITATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SKELETAL MUSCLE;

EID: 84975110943     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12451     Document Type: Review

References (110)

1. Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve 2015; 51: 638–56.
2. van Dooren SH, van Venrooij WJ, Pruijn GJ. Myositis-specific autoantibodies: detection and clinical associations. Auto Immun Highlights 2011; 2: 5–20.
3. Phan TG, Wong RC, Adelstein S. Autoantibodies to extractable nuclear antigens: making detection and interpretation more meaningful. Clin Diagn Lab Immunol 2002; 9: 1–7.
4. Tansley S, Gunawardena H. The evolving spectrum of polymyositis and dermatomyositis–moving towards clinicoserological syndromes: a critical review. Clin Rev Allergy Immunol 2014; 47: 264–73.
5. Satoh M, Vazquez-Del Mercado M, Chan EK. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 2009; 19: 219–28.
6. Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med 2000; 124: 71–81.
7. Tansley SL, Betteridge ZE, McHugh NJ. The diagnostic utility of autoantibodies in adult and juvenile myositis. Curr Opin Rheumatol 2013; 25: 772–7.
8. Sordet C, Goetz J, Sibilia J. Contribution of autoantibodies to the diagnosis and nosology of inflammatory muscle disease. Joint Bone Spine 2006; 73: 646–54.
9. Kang EH, Kuwana M, Okazaki Y et al. Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis-specific autoantibodies in dermatomyositis patients. Mod Rheumatol 2014; 24: 945–8.
10. Ghirardello A, Rampudda M, Ekholm L et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology 2010; 49: 2370–4.
11. Lega JC, Fabien N, Reynaud Q et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev 2014; 13: 883–91.
12. Mahler M, Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 2007; 6: 432–7.
13. Muro Y, Hosono Y, Sugiura K, Ogawa Y, Mimori T, Akiyama M. Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma. Arthritis Res Ther 2015; 17: 57.
14. Rider LG, Shah M, Mamyrova G et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine 2013; 92: 223–43.
15. Plestilova L, Gheorghe K, Lundberg I et al. Anti-PM-Scl autoantibodies in polymyositis and dermatomyositis. Ann Rheum Dis 2012; 71: 240.
16. Marie I, Lahaxe L, Benveniste O et al. Long-term outcome of patients with polymyositis/dermatomyositis and anti-PM-Scl antibody. Br J Dermatol 2010; 162: 337–44.
17. Coppo P, Clauvel JP, Bengoufa D, Oksenhendler E, Lacroix C, Lassoued K. Inflammatory myositis associated with anti-U1-small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome. Rheumatology 2002; 41: 1040–6.
18. Rigolet A, Musset L, Dubourg O et al. Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease. Medicine 2012; 91: 95–102.
19. Defendenti C, Atzeni F, Spina MF et al. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmun Rev 2011; 10: 150–4.
20. Marie I, Hatron PY, Dominique S et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 2012; 41: 890–9.
21. Betteridge ZE, Gunawardena H, McHugh NJ. Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther 2011; 13: 209.
22. Aggarwal R, Cassidy E, Fertig N et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 2014; 73: 227–32.
23. Hamaguchi Y, Fujimoto M, Matsushita T et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS ONE 2013; 8: e60442.
24. Aggarwal R, Bandos A, Reed AM et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014; 66: 740–9.
25. Stone KB, Oddis CV, Fertig N et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007; 56: 3125–31.
26. Yoshifuji H, Fujii T, Kobayashi S et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006; 39: 233–41.
27. Hozumi H, Enomoto N, Kono M et al. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study. PLoS ONE 2015; 10: e0120313.
28. Reichlin M, Mattioli M. Description of a serological reaction characteristic of polymyositis. Clin Immunol Immunopathol 1976; 5: 12–20.
29. Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 1985; 28: 796–803.
30. Kang EH, Nakashima R, Mimori T et al. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 2010; 11: 223.
31. Petri MH, Satoh M, Martin-Marquez BT et al. Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara. Arthritis Res Ther 2013; 15: R48.
32. Rider LG, Miller FW, Targoff IN et al. A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum 1994; 37: 1534–8.
33. Feldman BM, Reichlin M, Laxer RM, Targoff IN, Stein LD, Silverman ED. Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol 1996; 23: 1794–7.
34. Wedderburn LR, McHugh NJ, Chinoy H et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology 2007; 46: 1786–91.
35. Ghirardello A, Zampieri S, Iaccarino L et al. Anti-Mi-2 antibodies. Autoimmunity 2005; 38: 79–83.
36. Hengstman GJ, Vree Egberts WT, Seelig HP et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis 2006; 65: 242–5.
37. Wang HB, Zhang Y. Mi2, an auto-antigen for dermatomyositis, is an ATP-dependent nucleosome remodeling factor. Nucleic Acids Res 2001; 29: 2517–21.
38. Mammen AL, Casciola-Rosen LA, Hall JC, Christopher-Stine L, Corse AM, Rosen A. Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum 2009; 60: 3784–93.
39. Kashiwagi M, Morgan BA, Georgopoulos K. The chromatin remodeler Mi-2beta is required for establishment of the basal epidermis and normal differentiation of its progeny. Development 2007; 134: 1571–82.
40. Burd CJ, Kinyamu HK, Miller FW, Archer TK. UV radiation regulates Mi-2 through protein translation and stability. J Biol Chem 2008; 283: 34976–82.
41. Love LA, Weinberg CR, McConnaughey DR et al. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum 2009; 60: 2499–504.
42. Love LA, Leff RL, Fraser DD et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991; 70: 360–74.
43. Betteridge ZE, Gunawardena H, Chinoy H et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis 2009; 68: 1621–5.
44. Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szollosi L, Danko K. Four dermatomyositis-specific autoantibodies-anti-TIF1gamma, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev 2014; 13: 1211–9.
45. Tarricone E, Ghirardello A, Rampudda M, Bassi N, Punzi L, Doria A. Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods 2012; 384: 128–34.
46. Muro Y, Sugiura K, Akiyama M. Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Autoimmunity 2013; 46: 279–84.
47. Fujimoto M, Matsushita T, Hamaguchi Y et al. Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort. Ann Rheum Dis 2013; 72: 151–3.
48. Targoff IN, Mamyrova G, Trieu EP et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54: 3682–9.
49. Kaji K, Fujimoto M, Hasegawa M et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology 2007; 46: 25–8.
50. Targoff I, Trieu E, Levy-Neto M, Prasertsuntarsai T, Miller F. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-g) in dermatomyositis. Arthritis Rheum 2006; 54: 518.
51. Fujimoto M, Hamaguchi Y, Kaji K et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 2012; 64: 513–22.
52. Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1gamma antibodies in adults with dermatomyositis. J Am Acad Dermatol 2015; 72: 449–55.
53. Mohassel P, Rosen P, Casciola-Rosen L, Pak K, Mammen AL. Expression of the dermatomyositis autoantigen transcription intermediary factor 1gamma in regenerating muscle. Arthritis Rheumatol 2015; 67: 266–72.
54. Casciola-Rosen L, Nagaraju K, Plotz P et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201: 591–601.
55. Levine SM, Raben N, Xie D et al. Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. Arthritis Rheum 2007; 56: 2729–39.
56. Gunawardena H, Wedderburn LR, North J et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology 2008; 47: 324–8.
57. Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O'Callaghan A et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012; 64: 523–32.
58. Espada G, Maldonado Cocco JA, Fertig N, Oddis CV. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 2009; 36: 2547–51.
59. Matsuura E, Ishiguro N, Katsumata Y et al. Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-gamma. Eur J Dermatol 2012; 22: 668–71.
60. Muro Y, Ishikawa A, Sugiura K, Akiyama M. Clinical features of anti-TIF1-alpha antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-gamma or anti-Mi-2 autoantibodies. Rheumatology 2012; 51: 1508–13.
61. Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A et al. Anti-TIF1gamma antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays. Ann Rheum Dis 2012; 71: 993–6.
62. Oddis C, Fertig N, Goel A, Espada G, Confalone Gregorian M, Maldonado Cocco M. Clinical and serological characterisationof the anti-MJ antibody in childhood myositis. Arthritis Rheum 1997; 40: 139.
63. Targoff I, Trieu E, Levy-Neto M, Fertig N, Oddis C. Sera with autoantibodies to the MJ antigen react with NXP2. Arthritis Rheum 2007; 56: 787.
64. Gunawardena H, Wedderburn LR, Chinoy H et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60: 1807–14.
65. Ichimura Y, Matsushita T, Hamaguchi Y et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012; 71: 710–3.
66. Fiorentino DF, Chung LS, Christopher-Stine L et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum 2013; 65: 2954–62.
67. Ceribelli A, Fredi M, Taraborelli M et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 2012; 14: R97.
68. Tansley S, Betteridge Z, Gunawardena H et al. Clinical differences between adult and juvenile dermatomyositis assocaited with anti-NXP2 autoantibodies. Arthritis Rheum 2012; 64: S229.
69. Shinjo SK, Souza FH. Update on the treatment of calcinosis in dermatomyositis. Rev Bras Reumatol 2013; 53: 211–4.
70. Sugiura K, Muro Y, Akiyama M. Autoantibodies to nuclear matrix protein 2/MJ in adult-onset dermatomyositis with severe calcinosis. J Am Acad Dermatol 2012; 67: e167–8.
71. Tansley SL, Betteridge ZE, Shaddick G et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology 2014; 53: 2204–8.
72. Sato S, Hirakata M, Kuwana M et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52: 1571–6.
73. Sato S, Hoshino K, Satoh T et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60: 2193–200.
74. Nakashima R, Imura Y, Kobayashi S et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology 2010; 49: 433–40.
75. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65: 25–34.
76. Betteridge Z, Tansley S, Gunawardena H et al. Clinical phenotypes of Caucasian adult and juvenile dermatomyosits patients with anti-MDA5 autoantibodies. Arthritis Rheum 2012; 64: S715.
77. Hall JC, Casciola-Rosen L, Samedy LA et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res 2013; 65: 1307–15.
78. Chen Z, Cao M, Plana MN et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res 2013; 65: 1316–24.
79. Ceribelli A, Fredi M, Taraborelli M et al. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol 2014; 32: 891–7.
80. Muro Y, Sugiura K, Hoshino K, Akiyama M, Tamakoshi K. Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther 2011; 13: R214.
81. Gono T, Kawaguchi Y, Kuwana M et al. Brief report: association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum 2012; 64: 3736–40.
82. Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, Ariga T. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr 2011; 158: 675–7.
83. Tansley SL, Betteridge ZE, Gunawardena H et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther 2014; 16: R138.
84. Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 2013; 23: 496–502.
85. Koga T, Fujikawa K, Horai Y et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology 2012; 51: 1278–84.
86. Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology 2012; 51: 800–4.
87. Reeves WH, Nigam SK, Blobel G. Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci USA 1986; 83: 9507–11.
88. Rouster-Stevens KA, Pachman LM. Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol 2008; 35: 927–9.
89. Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990; 33: 1361–70.
90. Hengstman GJ, ter Laak HJ, Vree Egberts WT et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006; 65: 1635–8.
91. Wang L, Liu L, Hao H et al. Myopathy with anti-signal recognition particle antibodies: clinical and histopathological features in Chinese patients. Neuromuscul Disord 2014; 24: 335–41.
92. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50: 209–15.
93. Dimitri D, Andre C, Roucoules J, Hosseini H, Humbel RL, Authier FJ. Myopathy associated with anti-signal recognition peptide antibodies: clinical heterogeneity contrasts with stereotyped histopathology. Muscle Nerve 2007; 35: 389–95.
94. Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73: 420–8.
95. Whelan BR, Isenberg DA. Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. Rheumatology 2009; 48: 594–5.
96. Benveniste O, Drouot L, Jouen F et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011; 63: 1961–71.
97. Aggarwal R, Oddis CV, Goudeau D et al. Anti-signal recognition particle autoantibody ELISA validation and clinical associations. Rheumatology 2014; 54: 1194–9.
98. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010; 62: 2757–66.
99. Mammen AL, Gaudet D, Brisson D et al. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res 2012; 64: 1233–7.
100. Ramanathan S, Langguth D, Hardy TA et al. Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy. Neurol Neuroimmunol Neuroinflamm 2015; 2: e96.
101. Mammen AL, Chung T, Christopher-Stine L et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011; 63: 713–21.
102. Mammen AL, Pak K, Williams EK et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res 2012; 64: 269–72.
103. Watanabe Y, Suzuki S, Nishimura H et al. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan. Medicine 2015; 94: e416.
104. Allenbach Y, Drouot L, Rigolet A et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine 2014; 93: 150–7.
105. Rojana-Udomsart A, Bundell C, James I et al. Frequency of autoantibodies and correlation with HLA-DRB1 genotype in sporadic inclusion body myositis (s-IBM): a population control study. J Neuroimmunol 2012; 249: 66–70.
106. Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS ONE 2011; 6: e20266.
107. Pluk H, Van Engelen BG, Pruijn GJ. Anti-Mup44: the first inclusion body myositis-specific autoantibody. Autoantigens Autoantibodies AutoImmun 2011; 7: 210.
108. Pluk H, van Hoeve BJ, van Dooren SH et al. Autoantibodies to cytosolic 5’-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013; 73: 397–407.
109. Larman HB, Salajegheh M, Nazareno R et al. Cytosolic 5’-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013; 73: 408–18.
110. Herbert MK, Stammen-Vogelzangs J, Verbeek MM et al. Disease specificity of autoantibodies to cytosolic 5’-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis 2015; [Epub ahead of print].